Abstract. Background: Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an important early complication of antiretroviral therapy (ART) in countries with high rates of endemic TB, but data from South-East Asia are incomplete. Identification of prevalence, risk factors and treatment outcomes of TB-IRIS in Malaysia was sought. Methods: A 3-year retrospective study was conducted among TB-HIV co-infected patients treated at the University of Malaya Medical Centre. Simple and adjusted logistic regressions were used to identify the predictors for TB-IRIS while Cox regression was used to assess the influence of TB-IRIS on long-term CD4 T-cell recovery. Results: One hundred and fifty-three TB-HIV patients were enrolled, of whom 106 had received both anti-TB treatment (ATT) and ART. The median (IQR) baseline CD4 T-cell count was 52 cells mL -1 (13-130 cells mL -1 ). Nine of 96 patients (9.4%) developed paradoxical TB-IRIS and eight developed unmasking TB-IRIS, at a median (IQR) time of 27 (12-64) and 19 (14-65) days, respectively. In adjusted logistic regression analysis, only disseminated TB was predictive of TB-IRIS [OR: 10.7 (95% CI: 1.2-94.3), P = 0.032]. Mortality rates were similar for TB-IRIS (n = 1, 5.9%) and non-TB-IRIS (n = 5, 5.7%) patients and CD4 T-cell recovery post-ART was not different between the two groups (P = 0.363). Conclusion: Disseminated TB was a strong independent predictor of TB-IRIS in Malaysian HIV-TB patients after commencing ART. This finding underscores the role of a high pathogen load in the pathogenesis of TB-IRIS; so interventions that reduce pathogen load before ART may benefit HIV patients with disseminated TB.
Introduction
Tuberculosis (TB) is one of the major health problems among HIV-infected patients in resource-limited countries. South-East Asia harbours more than 40% of the global burden of TB cases. 1 In 2011, the incidence of TB in Malaysia was estimated at 81 cases per 100 000 population. Of a total of 21 000 TB cases, 1630 (9%) were co-infected with HIV. 2 Concurrent treatment of TB and HIV infection remains a challenge due to high pill burden, drug toxicity, drug-drug interactions and, tuberculosisassociated immune reconstitution inflammatory syndrome (TB-IRIS), which affects up to 30% of patients in resource-limited settings. There have been no data reported from Malaysia.
Tuberculosis-associated immune reconstitution inflammatory syndrome results from exaggerated inflammatory responses attributed to dysregulated immune recovery after commencing antiretroviral therapy (ART). 3 This syndrome can either present as a deterioration of existing disease (paradoxical TB-IRIS) or the appearance of new disease associated with previously subclinical infection (unmasking TB-IRIS) after ART initiation. 3 Although the symptoms of TB-IRIS can be as mild as solitary lymph node inflammation, TB-IRIS may manifest as potentially life-threatening complications, including meningitis and acute respiratory distress syndrome. It is therefore important that TB-IRIS is differentiated from other clinical complications of ART. In this retrospective study, we followed patients who initiated anti-TB therapy (ATT) and ART at University Malaya Medical Centre (UMMC), a teaching hospital in Kuala Lumpur, Malaysia. In the study, we aimed to investigate the prevalence of TB-IRIS, risk factors, and treatment outcomes including mortality rate and long-term CD4 T-cell recovery in TB-IRIS patients.
Methods

Study population and setting
The source population for this retrospective cohort study was all patients who received ATT at the Direct Observed Therapy Strategy (DOTS) Clinic at UMMC (Kuala Lumpur, Malaysia), from 1 January 2006 to 31 January 2010. New patients with pulmonary TB were given a standard ATT regimen for 6 months, consisting of 2 months with isoniazid, rifampicin, pyrazinamide, ethambutol followed by 4 months with isoniazid and rifampicin. Of 1579 TB patients identified, 153 who were co-infected with HIV-1 and had started ATT were included in the study. Patients with insufficient data, nontuberculous mycobacterial infection, or who were transferred to another centre or died before receiving ATT were excluded from the analysis. We also excluded a further 47 patients who did not commence ART due to death, transfer to another centre or default from follow up (Fig. 1 ). All participants with Malaysian nationality were Bacille de Calmette et Guérin (BCG) vaccinated and were screened and treated according to WHO Malaysia CPG guidelines for Management of Tuberculosis. 4 The study was approved by the ethics committee of UMMC (reference number: 661.8).
Data collection
Demographic information, medical history before ART initiation, baseline laboratory information, results of imaging studies, and information on clinical events after ART initiation were retrieved from patients' medical files. We examined medical files for 18 months post-ART to assess treatment outcomes.
Definitions
Based on the World Health Organization (WHO) criteria, 5 a case of TB was defined as a patient who was given a full course of ATT, whereas a definite case of TB required Mycobacterium tuberculosis complex to be identified from clinical specimens, either by culture or by a newer diagnostic method, such as molecular line probe assay. Extrapulmonary TB was defined as TB or definite TB (as defined above) that involved organs other than the lungs, that is, pleura, lymph nodes, skin, gastrointestinal tract and meninges. Disseminated TB was defined as TB or definite TB (as defined above) that involved more than one organ. Previously published case definitions were used to identify cases of TB-IRIS. 6 All possible TB-IRIS cases were evaluated by a committee comprised of physicians specialising in Infectious Diseases (n = 2) or Clinical Immunology (n = 1) to verify the diagnosis. Cases were then assigned to one of four groups: (1) Non-IRIS: TB-HIV co-infected patients who did not develop inflammatory disease after commencement of ART; (2) ART-associated TB: HIV patients who presented with active TB after initiation of ART but did not exhibit an exaggerated inflammatory reaction; (3) Paradoxical TB-IRIS: TB-HIV co-infected patients with TB disease at baseline, who were receiving ATT and who subsequently developed clinical deterioration within the first 3 months of ART; and (4) Unmasking TB-IRIS: HIV patients whose TB was subclinical on commencement of ART and was 'unmasked' within the first 3 months of ART and was associated with an exaggerated inflammatory reaction. Due to limitation in diagnostic capacity, alternative diagnoses (i.e. drug toxicity, failure/poor adherence to ATT) could not be completely ruled out for all events. Hence, an event was regarded as 'probable' when IRIS was the most likely cause of clinical deterioration and as 'possible' when IRIS was plausible where alternative explanations were equally plausible. 
Statistical analysis
The primary analysis was to compare patients with non-TB-IRIS, paradoxical TB-IRIS, and unmasking TB-IRIS.
Comparison of categorical variables was tested using the c 2 test or Fisher's exact test, whereas continuous variables (e.g. viral load, CD4) were compared using the non-parametric Kruskal-Wallis test, as these variables are not normally distributed.
Potential risk factors for TB-IRIS such as pre-ART demographic variables, HIV parameters, TB diagnosis, and time interval between ATT and ART were evaluated by simple logistic regression followed by adjusted logistic regression. The odds ratio and 95% confidence interval (CI) were estimated. Cox regression survival analysis was used to assess longitudinal CD4 T-cell recovery between TB-IRIS and non-TB-IRIS patients. CD4 T-cell recovery was defined as the time taken to achieve CD4 T-cell counts of >500 cells mL -1 . All analyses were conducted using SPSS version 20 (IBM, New York, NY, USA), and P-values <0.05 were considered significant.
Results
Demographic and baseline characteristics
One hundred and fifty-three patients who commenced ATT were included for baseline demographic analysis (Table 1) ; 125 (81.7%) were male; 62 were Chinese (40.5%), median age was 39 years (interquartile range (IQR) 34-49 years). Patients co-infected with HIV (n = 153) had a median baseline CD4 T-cell count of 52 cells mL -1 (IQR = 12-130 cells mL -1 ). Coinfections with HBV and HCV were 8.5% and 28.1%, respectively. Sputum acid-fast bacilli (AFB) smear was positive in 34% (n = 52) of patients and 48.4% (n = 74) were culture positive for M. tuberculosis. Almost half the patients had disseminated TB (n = 75, 49%). A tuberculin skin test was only performed on 49 (32%) TB-HIV co-infected patients, of whom eight (16%) had induration more than 10 mm (data not shown).
Incidence of TB-IRIS events
Of the 153 TB-HIV cases enrolled into the study, 106 commenced both ART and ATT. Twenty-two potential TB-IRIS cases were evaluated by the end-point review committee. Nine of 96 (9.4%) were confirmed to have paradoxical TB-IRIS within 12 weeks of initiating ART; one patient developed both probable paradoxical TB-IRIS of the lymph nodes and possible paradoxical TB-IRIS of the brain. In addition, eight patients had developed unmasking TB-IRIS before recruitment into the study cohort. There were inadequate data to determine the prevalence of unmasking TB-IRIS. A further two patients had developed ART-associated TB and were not considered for analyses of data on TB-IRIS. The remaining 87 patients experienced no adverse effects from starting ART.
Five cases were excluded due to: (1) rifampicin resistance (n = 1); (2) not fulfilling criteria for TB-IRIS (n = 2); (3) having a decline in plasma HIV RNA of <1 Log 10 (n = 1); and (4) no viral load data at disease onset (n = 1). Clinical manifestations in patients with TB-IRIS are presented in Table 2 .
TB-IRIS risk factor analysis
The pre-ART characteristics for non-TB-IRIS, paradoxical TB-IRIS, and unmasking TB-IRIS patients are shown in Table 3 . The three groups were similar with respect to age, gender, pre-ART HIV viral load, total white blood cell count, liver function tests and plasma level of C-reactive protein (CRP). Patients who developed TB-IRIS had significantly lower CD4 T-cell counts at baseline than non-TB-IRIS patients (P = 0.04). Furthermore, cases of disseminated TB were more prevalent among TB-IRIS patients as compared with non-IRIS patients (P = 0.001). In addition, TB-IRIS patients had a trend of having a lower haemoglobin level at baseline (P = 0.064) and a lower rate of diabetes mellitus before ART (P = 0.053). ART was initiated at a median (IQR) duration of 61.5 (30.3-87) and 36 (32-65.5) days after ATT for non-TB-IRIS and paradoxical TB-IRIS patients, respectively (P = 0.159). The median time to unmasking TB-IRIS development was 19 days (IQR = 14.5-65.3).
Using a logistic regression model, we investigated the association of pre-ART characteristics with the subsequent development of TB-IRIS (Fig. 2) . The variables that showed (Fig. 2) .
Treatment outcomes
The completion rate of ATT for patients with and without TB-IRIS was 70.6% vs 79.3%, respectively. The mortality rate was similar in TB-IRIS (n = 1, 5.3%) and non-TB-IRIS (n = 5, 5.8%) patients. The TB-IRIS patient who died had unmasking TB-IRIS that presented with an inflammatory syndrome and signs suggestive of TB in the second month of ART. This patient commenced ATT only after AFB was detected at week 27 of ART. Treatment failure (smear positive on sputum) after the completion of ATT was higher in TB-IRIS (n = 2, 10.5%) compared with non-TB-IRIS (n = 3, 3.5%) patients. The default rate on ART was similar in TB-IRIS and non-TB-IRIS patients (n = 1, 5.3%; n = 5, 5.8%), respectively. 
CD4 T-cell recovery on ART in TB-IRIS and non-TB-IRIS patients
To assess if TB-IRIS affects long-term CD4 T-cell recovery in TB-HIV co-infected patients, survival analyses were performed to compare the time taken to achieve a CD4 T-cell count of >500 cells mL -1 in TB-IRIS and non-TB-IRIS patients (Fig. 3) . The Cox regression survival plot showed that the rate of CD4 T-cell recovery in TB-IRIS patients was not significantly different to that for TB-HIV co-infected patients who did not develop TB-IRIS (P = 0.363).
Discussion
Mycobacterium tuberculosis is among the most frequently reported pathogens associated with an IRIS in HIV patients commencing ART. The prevalence of TB-IRIS varies throughout the world and is highly dependent on the population studied, specifically the degree of immune deficiency and the opportunistic infection burden. Earlier studies from developed countries reported a high incidence of TB-IRIS (29-43%). [9] [10] [11] [12] For resource-limited settings, the reported prevalence of TB-IRIS ranges from 12% in South Africa, 13 12-18% in Brazil, 14, 15 13% in India, 16 5-13% in Thailand, [17] [18] [19] and 29% in Uganda. 20 In this retrospective study, we report a prevalence of paradoxical TB-IRIS in Malaysia of 9.4% (nine out of 96 patients), which is similar to that of other developing countries.
Paradoxical and unmasking TB-IRIS are associated with the restoration of immune responses against mycobacterial antigens, which drive an inflammatory response that causes disease. Currently available data suggest that both adaptive and innate immune responses contribute to this process. 21 Perturbations of innate immune responses are most clear in paradoxical TB-IRIS, 22 and while Th1 responses increase, it is unclear to what extent this drives the inflammation or is a marker of the high pathogen load in that condition. 23 By contrast, markers of heightened Th1 responses against M. tuberculosis antigens are more prominent than markers of innate immune responses in unmasking TB-IRIS. 24, 25 Diagnosis of HIV infection in resource-limited settings can be challenging and is often delayed, with many patients seeking HIV care only after developing advanced immune deficiency and presenting with one or more opportunistic infections (OI). This is reflected in the low CD4 T-cell count and high coinfection rates in our study population, whereby the median baseline CD4 T-cell count was 52 cells mL -1 , and 44% of Table 1 ), that is, haemoglobin, CD4 T-cell count and disseminated TB were included in this predictive model. Additional variables that have been shown to be associated with increased risk of TB-IRIS in other studies, that is, viral load and AFB smear positivity and interval from ATT to ART were also included in the model. Association of all variables with risk for TB-IRIS was assessed in simple logistic and adjusted logistic regression models. Odds ratios for values below or above threshold levels were displayed in a forest plot; median and 95% CI were calculated. The Hosmer-Lemeshow value for this model was P = 0.825. Pre-ART, pre-antiretroviral therapy; CI, confidence interval; AFB, acid-fast bacilli; TB, tuberculosis; ATT, anti-tuberculosis therapy; ART, antiretroviral therapy; #, calculation did not include unmasking TB-IRIS cases; IRIS, immune reconstitution inflammatory syndrome. *P < 0.05.
TB-HIV co-infected patients presented with disseminated TB and 47% with multiple OIs (data not shown). TB-IRIS is associated with significant morbidity and expenditure of health resources. It would therefore be beneficial to predict the development of TB-IRIS. In the current study, a logistic regression model identified more advanced immunodeficiency (low CD4 T-cell count), presence of disseminated TB, low haemoglobin level and diabetes mellitus as predictors of TB-IRIS. Although these findings were in agreement with some other studies (with the exception of diabetes), 26 we found no association between high baseline viral load, or the interval between ATT to ART, and an increased risk of TB-IRIS that has been reported in several other studies. 6 For example, Narendran et al. demonstrated an independent association of a short interval between ATT and ART with a relative risk of 20.2 (IQR = 2.0-201.5) for developing TB-IRIS. 27 The discrepancy between that study and our study may have resulted from the differences in the interval between ATT and ART in the two studies [median (IQR) = 28 (14-47) days vs 57 days (31-85) in our study].
In our study, the adjusted logistic regression model demonstrated that disseminated TB was the only independent factor associated with TB-IRIS. Interestingly, we found no associations between lower baseline CD4 T-cell count, higher baseline viral load and shorter interval between ATT and ART, with an increased risk of TB-IRIS. These findings suggest an interaction between these variables and underline the importance of pre-ART mycobacterial antigen load in the pathogenesis of TB-IRIS. In a rabbit model of aerosol TB infection, the development and severity of TB-IRIS were dependent on the antigen load at the time of immune reconstitution. 28 Furthermore, Conesa-Botella et al. demonstrated that high urinary mycobacterial lipoarabinomannan (LAM) levels before ART initiation in TB-HIV co-infected patients increased the risk of TB-IRIS. 29 Measures that reduce pathogen load in HIV-TB patients before commencing ART might therefore decrease the risk of TB-IRIS. However, delaying ART to reduce the mycobacterial antigen load with ATT, in order to reduce the risk of TB-IRIS, is contraindicated in patients with CD4 T-cell counts <50 mL -1 , because delaying ART increases overall mortality. 30 Further research on possible measures to increase pathogen clearance before ART initiation is required.
The mortality rate for TB-IRIS patients (5.9%) in our study was similar to that for non-TB-IRIS patients (5.7%) and lower than that for other studies, which have reported mortality ranging from 10% to 38%. 13, 14, 16, 18, 31, 32 Notably, the only fatal case of TB-IRIS in our study was observed in a patient with unmasking TB-IRIS. Koenig et al. demonstrated that HIV patients who developed TB during the first 3 months of ART have a 3.5-fold increase in mortality rate compared with patients who present with TB at other times. 33 It is therefore important to detect, and commence treatment for, subclinical TB in patients with HIV before ART is commenced. 34 Using a Cox regression model, we showed that long-term CD4 T-cell recovery was not significantly different between TB-IRIS and non-IRIS patients (P = 0.363). This finding is similar to that found by Kumarasamy et al., 35 who demonstrated that TB-IRIS patients had higher CD4 T-cell counts than non-TB-IRIS patients at 6 months, 18 months and 24 months following ART initiation (P < 0.05), though counts were also higher before initiating ART. These findings suggest that TB-IRIS does not have a negative impact on the recovery of CD4 T-cell counts.
Our study has some limitations. First, our sample size was small. Second, due to the retrospective nature of the study, we could have missed clinical events that were not recorded in the medical records. Similarly, clinical features that may have been risk factors for TB-IRIS may not have been recorded.
In conclusion, we have shown that TB-HIV co-infected patients who present with disseminated TB exhibit the highest risk of developing TB-IRIS. Treatment strategies for enhancing pathogen clearance before commencing ART in HIV-TB co-infected patients should be investigated as a means of preventing TB-IRIS.
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